- Sagent Pharmaceuticals Announces the Launch of Amikacin Sulfate Injection, USP
- Nichi-Iko Pharmaceutical Co., Ltd to Acquire Sagent Pharmaceuticals for $21.75 Per Share in All Cash Transaction
- Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.
- Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10g Due to Presence of Dark Particulate Matter
- Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results
*Please see full prescribing and safety information, including boxed warning